<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244451</url>
  </required_header>
  <id_info>
    <org_study_id>CLL0809</org_study_id>
    <nct_id>NCT01244451</nct_id>
  </id_info>
  <brief_title>GIMEMA CLL0809 Study (BendOfa)</brief_title>
  <acronym>BendOfa</acronym>
  <official_title>A Single-Arm Multi-Center Trial of Bendamustine Given With Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL). EudraCT Number 2009-017663-42. GIMEMA CLL0809 Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last ten years there have been significant developments in CLL treatment. The advent&#xD;
      of fludarabine, rituximab and the association of chemo-immunotherapy have substantially&#xD;
      increased overall response rate, CR rate, time to progression and may also have an impact on&#xD;
      overall survival.&#xD;
&#xD;
      Even though, CLL remains incurable and all patients eventually relapse and progressively&#xD;
      become resistant to treatment. The development of an effective therapy that is not&#xD;
      cross-resistant with the ones currently available as front-line treatment, is one of the&#xD;
      clinical unmet needs within CLL.&#xD;
&#xD;
      BendOfa is a non comparative phase II trial designed to determine the therapeutic benefit of&#xD;
      bendamustine given together to ofatumumab in relapsed or resistant patients with CLL.&#xD;
&#xD;
      Bendamustine is approved by FDA for CLL treatment, it is an hybrid drug with alkylating&#xD;
      agents and purine analogue properties that may lack of cross resistance with fludarabine. It&#xD;
      was utilized in CLL as a single agent and its association with rituximab is currently under&#xD;
      clinical investigation.&#xD;
&#xD;
      Ofatumumab is a new fully human anti-CD20 monoclonal antibody with high in vitro efficacy on&#xD;
      CD20 low-expressing CLL cells. An early report showed that ofatumumab in single therapy is&#xD;
      effective in highly pre-treated refractory CLL patients.&#xD;
&#xD;
      Both drugs were generally well tolerated without unexpected untoward toxicity. On the basis&#xD;
      of these data, bendamustine and ofatumumab could be a new effective and well tolerated&#xD;
      combination for patients with relapsed and refractory CLL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Contributing to the Overall Response Rate</measure>
    <time_frame>After 8 months from therapy start (6 months of treatment plus 2 months from the last course to response evaluation)</time_frame>
    <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity According to CTCAE Version 4.0</measure>
    <time_frame>At 44 months from treatment start.</time_frame>
    <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 32 months: from the date of first BendOfa treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first.</time_frame>
    <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 44 months from treatment start.</time_frame>
    <description>Patients still alive will be censored at the moment of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or</condition>
  <condition>Patients With CLL Refractory (SD, PD or CR/PR &lt; 6 Months) Following no More Than Two Prior Treatment Lines</condition>
  <arm_group>
    <arm_group_label>Bendofa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine + Ofatumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.</description>
    <arm_group_label>Bendofa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.</description>
    <arm_group_label>Bendofa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CLL relapsing after an initial response (CR, PR ≥ 6 months) following no&#xD;
             more than two prior treatment lines; or&#xD;
&#xD;
          -  Patients with CLL refractory (SD, PD or CR/PR &lt; 6 months) following no more than two&#xD;
             prior treatment lines&#xD;
&#xD;
          -  Patients requiring treatment according to 2008 revised IWCLL guidelines&#xD;
&#xD;
          -  No more than 2 prior treatment lines&#xD;
&#xD;
          -  Age older or equal to 18 years&#xD;
&#xD;
          -  No active malignancies during the previous 5 years, with the exception of currently&#xD;
             treated basal cell or squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of&#xD;
             any origin&#xD;
&#xD;
          -  No prior treatment with conventional chemotherapy within the prior 4 weeks and with&#xD;
             monoclonal antibodies within the prior 16 weeks&#xD;
&#xD;
          -  ECOG performance status of ≤2 at study entry&#xD;
&#xD;
          -  Laboratory test results within these ranges:&#xD;
&#xD;
        Serum creatinine ≤ 2 x UNL Creatinine clearance ≥ 50 ml/min (Cockcroft and Gault formula)&#xD;
        Total bilirubin ≤ 2 x UNL (with exception of patients with Gilbert's syndrome) AST (SGOT)&#xD;
        and ALT (SGPT) ≤ 2 x UNL non attributable to CLL AST (SGOT) and ALT (SGPT) ≤ 10 x UNL&#xD;
        attributable to CLL&#xD;
&#xD;
          -  Female subjects of childbearing potential(FCBP) must:&#xD;
&#xD;
        Understands the potential teratogenic risk to the unborn child and the need for effective&#xD;
        contraception;&#xD;
&#xD;
        Be capable of complying with effective contraceptive measures.&#xD;
&#xD;
        Be informed and understand the potential consequences of pregnancy and the need to notify&#xD;
        her study doctor immediately if there is a risk of pregnancy.&#xD;
&#xD;
        Understand the need to commence the study treatment as soon as study drug is dispensed&#xD;
        following a negative pregnancy test.&#xD;
&#xD;
        Understand the need and accepts to undergo pregnancy testing based on the frequency&#xD;
        outlined in this protocol.&#xD;
&#xD;
        Females of childbearing potential (FCBP) enrolled in this protocol must agree to use two&#xD;
        reliable forms of contraception simultaneously or to practice complete abstinence from&#xD;
        heterosexual contact during the following time periods related to this study: 1) before&#xD;
        starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for&#xD;
        at least 28 days after study treatment discontinuation.&#xD;
&#xD;
        The two methods of reliable contraception must include one highly effective method and one&#xD;
        additional effective (barrier) method. FCBP must be referred to a qualified provider of&#xD;
        contraceptive methods if needed. The following are examples of highly effective and&#xD;
        additional effective methods of contraception:&#xD;
&#xD;
        Highly effective methods:&#xD;
&#xD;
          -  Intrauterine device (IUD)&#xD;
&#xD;
          -  Hormonal (birth control pills, injections, implants)&#xD;
&#xD;
          -  Tubal ligation&#xD;
&#xD;
          -  Partner's vasectomy&#xD;
&#xD;
        Additional effective methods:&#xD;
&#xD;
          -  Male condom&#xD;
&#xD;
          -  Diaphragm&#xD;
&#xD;
          -  Cervical Cap&#xD;
&#xD;
          -  Implants and levonorgestrel-releasing intrauterine systems are associated with an&#xD;
             increased risk of infection at the time of insertion and irregular vaginal bleeding.&#xD;
             Prophylactic antibiotics should be considered particularly in patients with&#xD;
             neutropenia.&#xD;
&#xD;
          -  Pregnancy testing.&#xD;
&#xD;
        FCBP must have two negative pregnancy tests prior to starting study drug.&#xD;
&#xD;
        FCBP must agree to have a medically supervised pregnancy test every 4 weeks including 4&#xD;
        weeks after the end of study treatment, except in the case of confirmed tubal&#xD;
        sterilization. This requirement also applies to women of childbearing potential who&#xD;
        practice complete and continued abstinence.&#xD;
&#xD;
        Females must agree to abstain from breastfeeding during study participation and for at&#xD;
        least 28 days after study drug discontinuation.&#xD;
&#xD;
        - Male patients must:&#xD;
&#xD;
        Understand the potential teratogenic risk if engaged in sexual activity with a pregnant&#xD;
        female or a female of childbearing potential.&#xD;
&#xD;
        Must practice complete abstinence or agree to use a prophylactic during sexual contact with&#xD;
        a pregnant female or a female of childbearing potential while participating in the study,&#xD;
        during dose interruptions and for at least 6 months following study drug discontinuation,&#xD;
        even if he has undergone a successful vasectomy.&#xD;
&#xD;
        If pregnancy or a positive pregnancy test does occur in the partner of a male study patient&#xD;
        during study participation, the investigator must be notified immediately.&#xD;
&#xD;
        - Female and male patients&#xD;
&#xD;
        should be instructed never to give this medicinal product to another person and to return&#xD;
        any unused capsules to the study doctor at the end of treatment.&#xD;
&#xD;
        Should not donate blood during therapy and for at least 28 days following discontinuation&#xD;
        of study drug.&#xD;
&#xD;
        Male patients should not donate semen or sperm while participating in the study, during&#xD;
        dose interruptions and for at least 6 months following study drug discontinuation&#xD;
&#xD;
          -  Signed written informed consent according to IGH/EU/GCP and Italian laws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline&#xD;
&#xD;
          -  Positive direct antiglobulin test (DAT) with clinical and laboratory signs of&#xD;
             hemolysis and/or autoimmune thrombocytopenia&#xD;
&#xD;
          -  Known transformation of CLL&#xD;
&#xD;
          -  Known CNS involvement of CLL&#xD;
&#xD;
          -  Known positivity for HIV or active HCV and HBV hepatitis.&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection requiring systemic anti-viral, antibiotic&#xD;
             or anti-fungal therapy.&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  Subjects who have current active hepatic or biliary disease (with exception of&#xD;
             patients with Gilbert's syndrome, asymptomatic gallstones or stable chronic liver&#xD;
             disease per investigator assessment)&#xD;
&#xD;
          -  Pregnant or Lactating Females.&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she was to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agostino Cortelezzi, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Direzione Scientifica - Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento Area Medica - Presidio Ospedaliero &quot;C. e G.Mazzoni&quot;</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia 1 - Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia e Oncologia Medica L.e A. Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ASL di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>9121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi, Università delgi studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Università degli Studi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le1 P.O. Vito Fazzi - U.O. di Ematologia</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Messina Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez. di medicina Interna Oncologia ed Ematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <zip>80143</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O. &quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Roma La Cattolica</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia &quot;Molinette&quot; Osp. Maggiore S. G. Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it/en/index.php</url>
    <description>GIMEMA Foundation Website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>January 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Ofatumumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendofa</title>
          <description>Bendamustine + Ofatumumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bendofa</title>
          <description>Bendamustine + Ofatumumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.85" lower_limit="46.12" upper_limit="81.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Contributing to the Overall Response Rate</title>
        <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
        <time_frame>After 8 months from therapy start (6 months of treatment plus 2 months from the last course to response evaluation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Contributing to the Overall Response Rate</title>
          <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity According to CTCAE Version 4.0</title>
        <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
        <time_frame>At 44 months from treatment start.</time_frame>
        <population>Number of patients experiencing 3 or &gt;3 Adverse Events (AEs) (both hematological and not hematological)</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity According to CTCAE Version 4.0</title>
          <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
          <population>Number of patients experiencing 3 or &gt;3 Adverse Events (AEs) (both hematological and not hematological)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
        <time_frame>Up to 32 months: from the date of first BendOfa treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Patients still alive will be censored at the moment of last follow-up.</description>
        <time_frame>At 44 months from treatment start.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Patients still alive will be censored at the moment of last follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Autoimmune hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Other toxicity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PIs of participating centres may disclose their centre's results only after the main study publication has been released, so that a single centre experience can be compared to the study overall results and give a more appropriate view of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfonso Piciocchi</name_or_title>
      <organization>GIMEMA</organization>
      <phone>+39 06 70390528</phone>
      <email>a.piciocchi@gimema.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

